Saturday, 16 June 2012

University Of Colorado Cancer Center-University Of Colorado Denver-Metastatic Breast Cancer

New target, new drug in breast cancer

(University of Colorado Denver) Many breast cancers depend on hormones including estrogen or progesterone for their survival and proliferation. Eight years of lab work at the University of Colorado Cancer Center and elsewhere suggest that the androgen receptor is an additional hormonal target in many breast cancers. (Source: EurekAlert! - Cancer) read more..

Drug combination offers new hope in fighting breast cancer

A new drug combination attacks breast cancer in a new way and appears much better at controlling cancer than the current standard of care. (Source: Health)MedWorm Sponsor Message: Have a look at The Breast Cancer Daily, the new breast cancer portal with all the latest breast cancer news and research powered by MedWorm, updated daily. read more..

Roche's targeted investigational breast cancer medicine, trastuzumab emtansine (T-DM1), reduced the risk of cancer worsening or death by 35 percent in pivotal phase III trial

Roche today announced that the Phase III EMILIA study of trastuzumab emtansine (T-DM1) met its co-primary endpoint, of a significant improvement in the time patients with HER2-positive metastatic breast cancer (mBC) lived without their disease getting worse (progression-free survival; PFS). (Source: Roche Media News) read more..

No comments:

Post a Comment